Jounce Therapeutics Presents INNATE Phase 1 and SELECT Clinical Trial data at the European Society of Medical Oncology Immuno-Oncology (ESMO – IO) Annual Congress
– INNATE trial Phase 1 dose escalation data showed JTX-8064 was well-tolerated as a single…
Four Inc. Secures Spot on Washington Technology’s Top 100 Government Contractors List for 11th Consecutive Year
Tat Hong Equipment Service Co., Ltd. Announces 2025/26 Annual Results